Vitamin B6, leukemia’s deadly addiction


Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and Memorial Sloan Kettering Cancer Center (MSK) suggest they could halt the growth of this cancer by limiting its ability to manipulate the enzyme that pushes B6 to make proteins essential for cell division.

Source: World Pharma NewsCategory: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

Bertolini F, Lemoli RM, Cea M
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, for treatment of various blood cancers. Here, we characterize a new multiple kinase inhibitor, ARQ531, and evaluate its mechanism of action in preclinical models of acute myeloid leukemia. Treatment with ARQ531, by producing global signaling pathway deregulation, resulted in impaired cell cycle progression and sur…

Source: HaematologicaCategory: Hematology Authors: Tags: Haematologica Source Type: research

Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development …

Yi He†, Wenyong Long† and Qing Liu*

Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China

Super-enhancers (SEs) refer to large clusters of enhancers that drive gene expressions. Recent data has provided novel insights in elucidating the roles of SEs in many diseases, including cancer. Many mechanisms involved in tumorigenesis and progression, ranging from internal gene mutation and rearrangement to external damage and inducement, have been demonstrated to be highly associated with SEs. Moreover, translocation, formation, deletion, or duplication of SEs themselves co…

In conclusion, based on its combined efficacy and safety, MEDI7247, a first-in class ADC is currently being evaluated in clinic for the treatment of ASCT2 positive hematological malignancies (NCT03106428).DisclosuresPore: Medimmune: Employment. Schifferli: Medimmune: Employment. Monks: Medimmune: Employment. Tammali: Medimmune: Employment. Borrok: Medimmune: Employment. Hurt: Medimmune: Employment. Flynn: Medimmune: Employment. Rebelatto: Medimmune: Employment. Townsley: Medimmue: Employment. Hinrichs: Medimmune: Employment. Dixit: Medimmune: Employment. Coats: Medimmune: Employment. Herbst: Medimmune: Employment. Tice: Medimmune: Employment.

Source: BloodCategory: Hematology Authors: Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Source Type: research

Bromodomain and extra terminal proteins (BETs) act as non-oncogene addiction targets1,2. BET inhibitors (BETi) are epigenetic drugs being explored as a promising therapeutic avenue in cancer, especially acute myeloid leukemia (AML)3,4,5. Although early clinical trials have highlighted the efficacy of this first-in-class therapy, chemotherapy resistance, which is commonly emerged during drug treatment, still hurdle the prevalence of BETi6,7.To seek for a strategy to overcome this hurdle, we carried out a combinatorial drug screening and discovered a synthetic lethality via combined inhibition of BRD4 and CDK7. Cyclin-depend…

Source: BloodCategory: Hematology Authors: Tags: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I Source Type: research

We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur.

Over the course of the …

Source: Fight Aging!Category: Research Authors: Tags: Newsletters Source Type: blogs

With the proposed changes to the Affordable Care Act (ACA), 20 million Americans are at risk of losing their health care coverage.

A survey, conducted by Brunswick Partners, found that “75 percent of Americans agree that the proposed changes to Medicaid in the AHCA are a bad idea. And that we should not allow 14 million Americans to become uninsured even if there is a potential to reduce Medicaid spending. These results are significant because they find majorities of Americans identifying as conservatives (55 percent), moderates (82 percent) and liberals (90 percent) are opposed to the AHCA’s Medicaid pro…

Publication date: 10 April 2017 Source:Cancer Cell, Volume 31, Issue 4 Author(s): Sebastian Mohr, Carmen Doebele, Federico Comoglio, Tobias Berg, Julia Beck, Hanibal Bohnenberger, Gabriela Alexe, Jasmin Corso, Philipp Ströbel, Astrid Wachter, Tim Beissbarth, Frank Schnütgen, Anjali Cremer, Nadine Haetscher, Stefanie Göllner, Arefeh Rouhi, Lars Palmqvist, Michael A. Rieger, Timm Schroeder, Halvard Bönig, Carsten Müller-Tidow, Florian Kuchenbauer, Ekkehard Schütz, Anthony R. Green, Henning Urlaub, Kimberly Stegmaier, R. Keith Humphries, Hubert Serve, Thomas Oellerich The transcription factor Me…

Source: Cancer CellCategory: Cancer & Oncology Source Type: research

By Stacy Simon New data from the Centers for Disease Control and Prevention (CDC) show that 40% of cancers diagnosed in the US may have a link to tobacco use. The report was published in the November 11, 2016 issue of Vital Signs. Tobacco use is the leading preventable cause of cancer and cancer deaths. It can cause cancer of the liver, colon and rectum, lung, oral cavity, esophagus, pharynx (throat), larynx (voice box), stomach, pancreas, bladder, kidney, and cervix, and acute myeloid leukemia. According to the CDC, about 660,000 people in the US were diagnosed each year between 2009 and 2013 with a cancer related to toba…

We reported recently that a loss of Plk2 in the developing mammary gland results in increased proliferation, hyperbranching, misoriented mitotic spindle assembly and defects in polarity (Villegas et al Development 2015). Loss of Plk2 was accompanied by increased expression of Plk1. Genetic rescue experiments, knocking down Plk1 in Plk2 null mouse mammary epithelium, and bimolecular fluorescence complementation assays, using wildtype Plk2 and a kinase dead mutant (KD) of Plk2 as bait, revealed that Plk2 regulates these processes through its direct interaction with Plk1. Our preliminary data suggest that loss of Plk2 results…

Source: Molecular Cancer ResearchCategory: Cancer & Oncology Authors: Tags: Animal Models: Poster Presentations – Proffered Abstracts Source Type: research

Source link